To include your compound in the COVID-19 Resource Center, submit it here.

Sumitomo gains Asian rights to Poxel's diabetes candidate

Poxel S.A. (Euronext:POXEL) granted Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) exclusive rights to Type II diabetes candidate imeglimin (PXL008) in Japan, China, South Korea, Taiwan and nine Southeast

Read the full 280 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE